Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay

Human Immunology

Volumn 70, Issue 8, 2009, Pages 584-588

  Phelan, Donna ^a   Mohanakumar, T ^b   Ramachandran, Sabarinathan ^b   Jendrisak, Martin D ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloantibody; Crossmatch; Donor specific; Luminex; Solid phase

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOCAL GLOMERULOSCLEROSIS; GRAFT FAILURE; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; SOLID PHASE ASSAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; DIAGNOSTIC ERRORS; EPITOPES; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MICROSPHERES; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 68049139250     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.05.007     Document Type: Article

References (21)

1. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
2. Johnson A.H., Rossen R.D., and Butler W.T. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 2 (1972) 215-226
3. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindications vs. risk. Am J Transpl 3 (2003) 1488-1500
4. Bielmann D., Honger G., Lutz D., Mihatsch M.J., Steiger J., and Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transpl 7 (2007) 626-632
5. Taylor C.J., Smith S.I., Morgan C.H., Stephenson S., Key T., Jones P., et al. Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time. Transplantation 69 (2000) 719-723
6. Cecka J.M., Zhang Q., and Reed E.F. Preformed cytotoxic antibodies in potential allograft recipients: recent data. Human Immunology 66 (2005) 343-349
7. Terasaki P.I. Humoral theory of transplantation. Am J Transplantation 3 (2003) 665-673
8. Gibney E.M., Cagle L.R., Freed B., Warnell S.E., Chan L., and Wiseman A.C. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 21 (2006) 2625-2629
9. Park W.D. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 3 (2003) 952-960
10. Gloor J.M., DeGoey S., Ploeger N., Gebel H., Bray R., Moore S.B., et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 78 (2004) 221-227
11. Higgins R., Hathaway M., Lowe D., Lam F., Kashi H., Tan L.C., et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 84 (2007) 876-884
12. Salama A.D. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 1 (2001) 260-269
13. Narayanan K., Jaramillo A., Phelan D.L., and Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 34 (2004) 2303-2312
14. Narayanan K., Phelan D., Jendrisak M.D., and Mohanakumar T. HLA class I antibody mediated accommodation of endothelial cells via the activation of P13K/cAMP dependent PKA pathway. Transplant Immunol 15 (2006) 187-197
15. Smith J.D., Hamour I.M., Banner N.R., and Rose M.L. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 7 (2007) 2809-2815
16. Worthington J.E., Martin S., Dyer P.A., and Johnson R.W. An association between posttransplant antibody production and renal transplant rejection. Transplant Proc 33 (2001) 475-476
17. Pelletier R.P., Hennessy P.K., Adams P.W., VanBuskirk A.M., Ferguson R.M., and Orosz C.G. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2 (2002) 134-141
18. Piazza A., Poggi E., Borrelli L., Servetti S., Monaco P.I., Buonomo O., et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 71 (2001) 1106-1112
19. Lee P.C. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74 (2002) 1192-1194
20. Harmer A.W., Koffman C.G., Heads A.J., and Vaughan R.W. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. Transplant Proc 27 (1995) 666-667
21. Bian H., and Reed E.F. Allo antibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol 163 (1999) 1010-1018